BioLargo is pleased to welcome a new member to our team,
Julian Bejarano, PhD, who will hold the position of Director of Product
Development at Clyra Medical Technologies. Julian will work closely with our
leadership group to help create and refine new medical products under the
umbrella of our Clyra advanced wound care product line. As Director of Product
Development for Clyra, Julian will be responsible for bringing health care
products to market from concept to commercialization. He will use the patented
antimicrobial technology owned by Clyra to develop new products and formulas
for dental applications, skin care, wound healing, skin regeneration, and bone
replacement procedures, as well as other relevant products related to the
healthcare field. Dr. Bejarano will evaluate nanoencapsulation approaches to
boost the efficacy of active agents and improve the biocompatibility and
physical features of the final product. He will also lead the planning, design
and execution of studies to provide proof of concept, safety, and efficacy
depending on the regulatory pathway of product development. We are very excited
about the value he will add to Clyra and the entire company.
Julian is an expert scientific researcher with more than 11
years of experience leading fundamental and applied research projects related
to materials science and nanotechnology. In particular, he has six years of
experience in projects related to biomaterials for regenerative medicine and
multifunctional nanoparticles for controlled drug delivery. Julian holds a Materials
Engineering degree and a Masters in Materials Engineering from the Universidad
del Valle, Colombia. He also holds a PhD in Engineering Sciences with emphasis
in Materials Science from the Universidad de Chile, Chile. Julian was a
visiting researcher during his PhD studies at the Institute of Biomaterials at
the University of Erlangen-Nuremberg, Germany. Following his doctorate studies,
Dr. Bejarano was a postdoctoral fellow at the Advanced Center for Chronic
Diseases in Chile for three years and Research Advisor for the Group of Polymer
Engineering at the Universidad de Chile. Moreover, he has outstanding skills in
project management, R&D, and innovation. His projects have been focused on
the development and characterization of composites materials based on metals,
polymers and ceramics, synthesis of multifunctional nanoparticles,
encapsulation of therapeutic agents, and biological evaluation of materials.
His findings in materials research have been published by prestigious
international journals and he has presented at several international events
related to biomaterials and materials science.
Steve Harrison, President of Clyra Medical Technologies
commented, “Julian brings unique and highly specialized knowledge and talent to
the company. He will play an important role in helping us expand our product portfolio
as we gear up for our commercial launch.”
What is a BioLargo
Spotlight?
It’s an exciting time
at BioLargo. We’re moving fast, and it can be difficult to keep our
stockholders and the investing public informed of our progress. In light of
this, we will be posting a series of short articles titled “BioLargo
Spotlight”, highlighting certain business activities and other important
information in between our required SEC filings. Of course, these do not
replace our public filings, which contain more complete information than can be
delivered in this forum, and thus we urge you to carefully read and rely on
those filings for definitive information, and to review our risk factors and
caution regarding forward-looking statements. We are optimistic about our
business as we work hard to continue to grow and ultimately generate profits
for our stockholders.
Legal Disclaimer
Our attorneys remind
us that while we believe these developments are important and that these small
victories could add up and lead to big victories, at this stage they do not
rise to the level of an official material disclosure. As the size and magnitude
of these developments become material, we will naturally report that
information in an 8-K and our regular SEC filings.
No comments:
Post a Comment